News
China’s 3SBio Soars on Granting Pfizer New Cancer Drug Rights in USD6 Billion Deal
3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF for cancer treatment, according to the agreement announced yesterday. The deal also includes an option for Pfizer to acquire commercialization rights in China.
The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...
Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...
Pfizer (NYSE:PFE) is overhauling its cardiometabolic ... antagonist and pursuing external opportunities that could include partnerships or acquisitions. That strategic pivot comes as shares ...
The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...
Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...
Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...
Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...
Hosted on MSN1mon
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?With the Trump administration imposing sweeping tariffs, fears of a global recession ... sales of Pfizer’s COVID products, Comirnaty and Paxlovid, which it developed in partnership with BioNTech ...
Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback